European Heart Journal Advance Access published online on June 2, 2005
European Heart Journal, doi:10.1093/eurheartj/ehi337
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Cardiology, Centre Hôpital Pitié-Salpêtrière, Bureau 2-236, 47, Boulevard de l'Hôpital, 75013 Paris, France
* To whom correspondence should be addressed. Aims To determine whether low-molecular-weight heparin (LMWH)+glycoprotein (GP) IIb/IIIa inhibitors provide greater benefit than unfractionated heparin (UFH)+GP IIb/IIIa inhibitors, irrespective of renal status. Methods and results Patients in the Global Registry of Acute Coronary Events (GRACE) were divided into three groups according to creatinine clearance (CrCl): normal renal function (CrCl >60 mL/min), moderate renal dysfunction (30<CrCl Conclusion In patients with renal dysfunction and non-ST-segment elevation ACS, bleeding complications are more frequent and outcomes appear worse in individuals treated with UFH compared with LMWH. Combination therapy with LMWH and GP IIb/IIIa inhibitors appears to be better tolerated than with UFH and GP IIb/IIIa inhibitors.
Received November 4, 2004
Revised April 19, 2005
Accepted April 28, 2005
Clinical research
Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events
2
Department of Cardiology, Centre Hôpital Pitié-Salpêtrière, Bureau 2-236, 47, Boulevard de l'Hôpital, 75013 Paris, France
3 Department of Internal and Cardiovascular Medicine, University of Perugia, Perugia, Italy
4 Department of Cardiology, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
5 Department of Cardiology, ICYCC Favaloro Foundation, Buenos Aires, Argentina
6 Department of Cardiology, Hospital Universitario Gregorio Marañon, Madrid, Spain
7 Department of Cardiology, Krankenhaus Düren, Düren, NRW, Germany
8 University of Massachusetts Medical School, Worcester, MA, USA
Gilles Montalescot, E-mail: gilles.montalescot{at}psl.ap-hop-paris.fr
![]()
Abstract
60 mL/min), and severe (CrCl
30 mL/min) renal dysfunction. Data were analysed from 11 881 patients with acute coronary syndrome (ACS). Patients with moderate (n=3705) or severe (n=982) renal dysfunction were at higher risk of adverse outcomes than those with normal renal function. Decreasing CrCl was an independent predictor of mortality at 30 days and in-hospital major bleeding. LMWH+GP IIb/IIIa inhibitors were used significantly less frequently in patients with severe (2.0%) or moderate (3.1%) renal dysfunction than in those with normal function (3.9%, P=0.0056). LMWH alone was more beneficial than UFH alone, irrespective of renal status. LMWH alone was an independent predictor of 30 day survival [odds ratio (OR) 0.56; 95% confidence interval (CI) 0.43-0.73] and lower risk of in-hospital bleeding (OR 0.66; 95% CI 0.48-0.92). Bleeding rates were significantly lower with LMWH+GP IIb/IIIa inhibitors than those with UFH+GP IIb/IIIa inhibitors. Use of UFH+GP IIb/IIIa inhibitors was an independent predictor of bleeding (OR 2.02; 95% CI 1.42-2.90) compared with UFH alone.![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
E. A Nutescu, S. A Spinler, A. Wittkowsky, and W. E Dager Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings Ann. Pharmacother., June 1, 2009; 43(6): 1064 - 1083. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Ndrepepa, P. B. Berger, J. Mehilli, M. Seyfarth, F.-J. Neumann, A. Schomig, and A. Kastrati Periprocedural Bleeding and 1-Year Outcome After Percutaneous Coronary Interventions Appropriateness of Including Bleeding as a Component of a Quadruple End Point. J. Am. Coll. Cardiol., February 19, 2008; 51(7): 690 - 697. [Abstract] [Full Text] [PDF] |
||||
![]() |
Authors/Task Force Members, J.-P. Bassand, C. W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernandez-Aviles, K. A.A. Fox, D. Hasdai, E. M. Ohman, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology Eur. Heart J., July 1, 2007; 28(13): 1598 - 1660. [Full Text] [PDF] |
||||
![]() |
K. A.A. Fox, E. M. Antman, G. Montalescot, S. Agewall, B. SomaRaju, F. W.A. Verheugt, J. Lopez-Sendon, H. Hod, S. A. Murphy, and E. Braunwald The Impact of Renal Dysfunction on Outcomes in the ExTRACT-TIMI 25 Trial J. Am. Coll. Cardiol., June 12, 2007; 49(23): 2249 - 2255. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. V. Rao, J. A. Eikelboom, C. B. Granger, R. A. Harrington, R. M. Califf, and J.-P. Bassand Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes Eur. Heart J., May 2, 2007; 28(10): 1193 - 1204. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Lim, F. Dentali, J. W. Eikelboom, and M. A. Crowther Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency Ann Intern Med, May 2, 2006; 144(9): 673 - 684. [Abstract] [Full Text] [PDF] |
||||



